Kamalesh Sankhala, MD
Medical Oncology · Beverly Hills, CANPI 1225214174
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Aadi Bioscience, Inc. at 36.8% of the total.
Across 316 payments — averaging $502.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aadi Bioscience, Inc.$58K
- Daiichi Sankyo Inc.$48K
- Springworks Therapeutics, Inc.$31K
- Bayer$9K
- Deciphera Pharmaceuticals Inc.$8K
- Novartis$860
- plus $4K from 35 others
Across 126 payments — averaging $15,267 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1.1M
- Aadi Bioscience, Inc.$324K
- Boehringer Ingelheim Pharma GmbH & Co.kg$215K
- Bayer$172K
- UCB SA$49K
- Amgen$38K
- plus $47K from 5 others
What the payments were for
- Consulting fees$50,54332%
- Speaking & faculty fees$80,62651%
- Travel & lodging$17,70611%
- Food & beverage$8,9266%
- Education$2740%
- Other$8321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aadi Bioscience, Inc. | 66 | $58,426 |
| Daiichi Sankyo Inc. | 60 | $47,960 |
| Springworks Therapeutics, Inc. | 24 | $31,177 |
| Bayer | 13 | $9,094 |
| Deciphera Pharmaceuticals Inc. | 22 | $7,699 |
| Novartis | 11 | $860 |
| Johnson & Johnson | 27 | $774 |
| Merck | 12 | $348 |
| Cardinal Health 108 LLC | 3 | $256 |
| EMD Serono, Inc. | 6 | $202 |
| Pfizer | 10 | $200 |
| Intera Oncology, Inc | 1 | $168 |
| Galvanize Therapeutics, Inc | 2 | $164 |
| E.r. Squibb & Sons, L.L.C. | 7 | $156 |
| Incyte Corporation | 6 | $142 |
| AstraZeneca | 5 | $128 |
| Sobi, Inc | 2 | $107 |
| Gilead | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Genentech USA, Inc. | 3 | $86 |
| Array Biopharma Inc | 3 | $81 |
| Eisai Inc. | 4 | $72 |
| Amneal Pharmaceuticals LLC | 3 | $71 |
| Karyopharm Therapeutics Inc. | 2 | $66 |
| Caris MPI, Inc. | 2 | $58 |
| Amgen | 2 | $51 |
| Tersera Therapeutics LLC | 1 | $36 |
| Pharmacosmos Therapeutics Inc. | 1 | $36 |
| Spectrum Pharmaceuticals Inc. | 1 | $35 |
| Sanofi | 1 | $31 |
| Avyxa Pharma, LLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $28 |
| GSK | 1 | $23 |
| Seagen Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| Tempus AI, Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $18 |
| Itamar Medical Inc | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FYARRO$57,648
- Turalio$46,426
- OGSIVEO$31,131
- Nexavar$6,088
- VIMSELTINIB$5,098
- Vitrakvi$2,711
- QINLOCK$2,200
- Intera 3000 Implantable Pump$168
- RYBREVANT$149
- CARVYKTI$149
- ALIYA SYSTEM$104
How this compares
$158,906 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 18 | $208,967 |
| IbrancePalbociclib | 12 | $180,281 |
| VenclextaVenetoclax | 12 | $178,979 |
| VotrientPazopanib Hcl | 11 | $75,889 |
| UdenycaPegfilgrastim-Cbqv | 11 | $44,064 |
| Imatinib Mesylate | 25 | $15,313 |
| EliquisApixaban | 21 | $14,103 |
| Ondansetron Hcl | 41 | $1,456 |
| Prochlorperazine Maleate | 39 | $812 |
| Ondansetron OdtOndansetron | 12 | $534 |
| Dexamethasone | 19 | $182 |
| Metoclopramide Hcl | 24 | $140 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $103 |
| Prednisone | 19 | $91 |
| Acyclovir | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $20 | $208,96718 claims |
| PfizerIbrance, Eliquis | $200 | $194,38533 claims |
| NovartisVotrient | $860 | $75,88911 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $8613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 379 medical oncology providers in California.
Other medical oncology in Beverly Hills
- Noam DrazinBeverly Hills$1.4M
- Stephen SherwinSan Francisco$6.9M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.